Skip to content
Inpefa, Zynquista(sotagliflozin)
Inpefa, Zynquista (sotagliflozin) is a small molecule pharmaceutical. Sotagliflozin was first approved as Zynquista on 2019-04-26. It has been approved in Europe to treat type 1 diabetes mellitus. The pharmaceutical is active against sodium/glucose cotransporter 2 and sodium/glucose cotransporter 1.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nutritional and metabolic diseasesD009750
endocrine system diseasesD004700
immune system diseasesD007154
Trade Name
FDA
EMA
Inpefa
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Sotagliflozin
Tradename
Company
Number
Date
Products
INPEFALEXICON PHARMS INCN-216203 RX2023-05-26
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
inpefaNew Drug Application2023-06-05
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A10: Drugs used in diabetes
— A10B: Blood glucose lowering drugs, excl. insulins
— A10BK: Sodium-glucose co-transporter 2 (sglt2) inhibitors
— A10BK06: Sotagliflozin
HCPCS
No data
Clinical
Clinical Trials
50 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Heart failureD006333EFO_0003144I50—111—3
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 2 diabetes mellitusD003924EFO_0001360E1110213——25
Type 1 diabetes mellitusD003922EFO_0001359E10243——8
Chronic renal insufficiencyD051436N18——3——3
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Diabetes mellitusD003920EFO_0000400E08-E1351———6
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—13————13
Renal insufficiencyD051437HP_0000083N192————2
Hepatic insufficiencyD0485501————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSOTAGLIFLOZIN
INNsotagliflozin
Description
Sotagliflozin, sold under the brand name Inpefa among others, is a medication used to reduce the risk of death due to heart failure.
Classification
Small molecule
Drug classphlorozin derivatives, phenolic glycosides
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCOc1ccc(Cc2cc([C@@H]3O[C@H](SC)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1
Identifiers
PDB—
CAS-ID1018899-04-1
RxCUI—
ChEMBL IDCHEMBL3039507
ChEBI ID—
PubChem CID24831714
DrugBankDB12713
UNII ID6B4ZBS263Y (ChemIDplus, GSRS)
Target
Agency Approved
SLC5A2
SLC5A2
SLC5A1
SLC5A1
Organism
Homo sapiens
Gene name
SLC5A2
Gene synonyms
SGLT2
NCBI Gene ID
6524
Protein name
sodium/glucose cotransporter 2
Protein synonyms
Low affinity sodium-glucose cotransporter, Na(+)/glucose cotransporter 2, solute carrier family 5 (sodium/glucose cotransporter), member 2, solute carrier family 5 (sodium/glucose transporter), member 2, Solute carrier family 5 member 2
Uniprot ID
P31639
Mouse ortholog
Slc5a2 (246787)
sodium/glucose cotransporter 2 (Q923I7)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,032 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
548 adverse events reported
View more details